Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 18/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567399 | 0.86 | CCR1 (0.69) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL568763 | 0.84 | CCR1 (0.62) | CCR1CYP3A4KCNH2ADRB1SMO | |
| SCHEMBL567203 | 0.84 | CCR1 (0.62) | CCR1CYP3A4KCNH2ADRB1SMO | |
| SCHEMBL567816 | 0.82 | CCR1 (0.63) | CCR1CYP3A4KCNH2ADRB1SMO | |
| SCHEMBL567417 | 0.81 | CCR1 (0.78) | CCR1CYP3A4KCNH2ADRB1SMO | |
| SCHEMBL568174 | 0.80 | CCR1 (0.76) | CCR1CYP3A4KCNH2ADRB1SMO | |
| SCHEMBL567195 | 0.80 | CCR1 (0.59) | CCR1CYP3A4KCNH2ADRB1SMO | |
| SCHEMBL567881 | 0.79 | CCR1 (0.69) | CCR1CYP3A4KCNH2ADRB1SMO | |
| SCHEMBL567656 | 0.79 | CCR1 (0.69) | CCR1CYP3A4KCNH2ADRB1SMO | |
| SCHEMBL568004 | 0.79 | CCR1 (0.58) | CCR1CYP3A4KCNH2ADRB1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163918-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20120035370-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035370-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | CCR1 1/4885CYP3A4 1936/4885KCNH2 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.